Polio vaccines are inexpensive, easily available, already approved—and they might work wonders against COVID-19

Credit: Ezra Ecayan

Recent reports indicate that COVID-19 may result in suppressed innate immune responses. Therefore, stimulation by live attenuated vaccines [such as the polio vaccine] could increase resistance to infection by the causal virus, severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2). Clinical studies of this hypothesis could begin immediately. [Tuberculosis vaccine] trials have already been initiated by immunizing frontline health care workers. The endpoint of these trials is the difference in COVID-19 incidence, duration, and severity between immunized and unimmunized populations.

We propose the use of OPV to ameliorate or prevent COVID-19. Both poliovirus and coronavirus are positive-strand RNA viruses; therefore, it is likely that they may induce and be affected by common innate immunity mechanisms. There are multiple important advantages to using OPV: a strong safety record, the existence of more than one serotype that could be used sequentially to prolong protection, low cost, ease of administration, and availability. Over 1 billion doses of OPV are produced and used annually in more than 140 countries. Although the supply of BCG is limited, a small fraction of OPV intended for the suspended polio eradication campaign would be sufficient for the clinical trials, and provided a positive outcome, production could likely be scaled up quickly.

Related article:  Analysis: Is COVID-19 a blessing or a curse to Africa?

If proven to be effective against COVID-19, emergency immunization with live attenuated vaccines could be used for protection against other unrelated emerging pathogens.


Read the original post

Outbreak Daily Digest
Biotech Facts & Fallacies
GLP Podcasts
Infographic: Deaths from COVID-19 are far higher than reported estimates

Infographic: Deaths from COVID-19 are far higher than reported estimates

More than 2.8 million people have lost their lives due to the pandemic, according to a Wall Street Journal analysis ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend